Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):31-7. doi: 10.1016/j.ijrobp.2009.04.080. Epub 2009 Oct 26.
To determine the impact of stereotactic radiotherapy on the quality of life of patients with inoperable early-stage non-small-cell lung cancer (NSCLC). Overall survival, local tumor control, and toxicity were also evaluated in this prospective study.
From January 2006 to February 2008, quality of life, overall survival, and local tumor control were assessed in 39 patients with pathologically confirmed T1 to 2N0M0 NSCLC. These patients were treated with stereotactic radiotherapy. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30 and the QLQ LC13 lung cancer-specific questionnaire were used to investigate changes in quality of life. Assessments were done before treatment, at 3 weeks, and at 2, 4, 6, 9, and 12 months after treatment, until death or progressive disease. Toxicity was evaluated using common terminology criteria for adverse events version 3.0.
Emotional functioning improved significantly after treatment. Other function scores and QLQ C30 and QLQ LC13 lung symptoms (such as dyspnea and coughing) showed no significant changes. The overall 2-year survival rate was 62%. After a median follow-up of 17 months, 1 patient had a local recurrence (3%). No grade 4 or 5 treatment-related toxicity occurred. Grade 3 toxicity consisted of thoracic pain, which occurred in 1 patient within 4 months of treatment, while it occurred thereafter in 2 patients.
Quality of life was maintained, and emotional functioning improved significantly after stereotactic radiotherapy for stage I NSCLC, while survival was acceptable, local tumor control was high, and toxicity was low.
确定立体定向放疗对不能手术的早期非小细胞肺癌（NSCLC）患者生活质量的影响。本前瞻性研究还评估了总生存率、局部肿瘤控制和毒性。
从 2006 年 1 月至 2008 年 2 月，对 39 例经病理证实的 T1 至 2N0M0 NSCLC 患者进行了生活质量、总生存率和局部肿瘤控制评估。这些患者接受了立体定向放疗。采用欧洲癌症研究与治疗组织（EORTC）生活质量问卷（QLQ）C30 和 QLQ LC13 肺癌特异性问卷来调查生活质量的变化。在治疗前、治疗后 3 周以及治疗后 2、4、6、9 和 12 个月进行评估，直至死亡或疾病进展。使用不良事件常用术语标准 3.0 评估毒性。
治疗后情绪功能显著改善。其他功能评分以及 QLQ C30 和 QLQ LC13 肺癌症状（如呼吸困难和咳嗽）没有显著变化。总的 2 年生存率为 62%。在 17 个月的中位随访后，1 例患者局部复发（3%）。没有发生 4 级或 5 级与治疗相关的毒性。3 级毒性包括胸痛，1 例患者在治疗后 4 个月内发生，此后有 2 例患者发生。
立体定向放疗治疗 I 期 NSCLC 后，生活质量得以维持，情绪功能显著改善，而生存率可接受，局部肿瘤控制率高，毒性低。
